[{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Azeloglycine","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sanofi \/ Perrigo","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Perrigo"},{"orgOrder":0,"company":"Kymab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"KY1005","moa":"OX40L","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kymab \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kymab \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Azeloglycine","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sanofi \/ Perrigo","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Perrigo"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Regeneron"},{"orgOrder":0,"company":"Sanofi","sponsor":"Kymab","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Amlitelimab","moa":"OX40L","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":1.45,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":1.45,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Kymab","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Amlitelimab","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":1.45,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":1.45,"dosageForm":"","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Regeneron"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Amlitelimab","moa":"OX40L","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Regeneron"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"ORI-001","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ SANOFI","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ SANOFI"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"C4X Discovery","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"IL-17A","graph1":"Dermatology","graph2":"Preclinical","graph3":"Sanofi","amount2":0.42999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"KT-474","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Amlitelimab","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Biosion","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BSI-045B","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"SAR444656","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":2.1499999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":2.1499999999999999,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"SAR444656","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":2.1499999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":2.1499999999999999,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Amlitelimab","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Formation Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Series D Financing","leadProduct":"ASN008","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0.37,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.37,"dosageForm":"Gel","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Sanofi"}]
Find Dermatology Clinical Drug Pipeline Developments & Deals by Sanofi
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.